Human 3 with Brom and Sam27 Mai 2025

Can electricity cure brain cancer? Ben Woodington of Coherence Neuro on BCIs in oncology

Ben Woodington is the cofounder and CEO of Coherence Neuro. Coherence's lead product, the SOMA-1, is a brain computer interface (BCI) that is designed to treat Glioblastoma (a type of brain cancer). Coherence's cancer focus sets them apart from other BCI companies like Neuralink and Synchron. Ben joins Brom Rector on the podcast to discuss:

(0:00) - Intro

(1:38) - What does BCI (brain-computer interface) even mean?

(3:55) - The deadly brain cancer that Coherence is treating

(8:01) - How can you treat cancer with electricity?

(9:54) - Coherence’s billion dollar comp

(12:52) - How does the Coherence device actually work?

(19:00) - How MRI makes brain computer interface

development difficult

(20:30) - Ben’s startup journey

(21:30) - How implants are more convenient than drugs

(24:55) - Is neurotech getting overhyped?

(28:04) - Are the obvious ideas taken?

(29:00) - What will enable the next generation of BCIs?

(30:30) - What is the best dimension along which to analyze BCIs?

(33:36) - Will people have multiple BCIs simultaneously?

(35:45) - Is it easier to get a device approved by the FDA than a drug?

(40:15) - When is Coherence’s first trial?

(42:00) - It’s capital allocators all the way down (clip)

(44:20) - Advice for PhD students considering starting a company

Check out Coherence here: https://coherenceneuro.com/

And check out Brom's VC fund, XEIA Venture Partners here: https://www.xeiavp.com/

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(33)

Dave Messina - YC founder turned investor talks TechBio

Ever wondered what Pioneer Fund’s Future of Health Fund is excited about? Want to know how to impress Dave Messina? Are you curious about how different funds communicate and interact?Give a listen to ...

6 Jul 1h 16min

$HIMS Q2 Results - our take as healthcare venture capitalists

Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly. W...

5 Aug 20251h 24min

Investing in Psychedelic BioTech [August 2025 webinar replay]

Watch the video recording on YouTube: https://youtu.be/BM6x59oMnKg?si=qF0xDvgUMvU60ctP2025 has been the start of a bull period for psychedelic medicine.Psychedelic Biotechs like GH Research, Compass ...

30 Jul 202558min

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

The past few years have been rough for psychedelic and shroom stocks, but recent news from ATAI (and Recognify), Compass Pathways and GH Research + positive regulatory tailwinds from RFK and MAHA make...

29 Jul 202516min

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Ryan Field is the CEO of Kernel, a brain-computer interface company founded by Bryan Johnson. Kernel is a cutting edge, non-invasive BCI that uses fNIRS to image the brain. Imagine if getting an MRI w...

22 Jul 20251h 33min

How to start a VC fund

I interviewed Michael Huseby to learn about his life story and his new book: Fundamentals: Your Friendly Guide to Investment Funds and SyndicationsThis is a great listen for anyone interested in start...

15 Jul 20251h 20min

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Replay of our webinar on investing in brain computer interfaces. Join our upcoming July 30th event on investing in psychedelic biotech: psybio.org

12 Jul 20251h 9min

Designing Novel Brain Drugs with Xylo Bio

Xylo is a biotech startup that is using computational methods to design novel brain drugs to treat mental health disorders and neurodegeneration. Many of their drug candidates are inspired by naturall...

8 Jul 20251h